Effects of perindopril on cardiovascular remodeling

American Journal of Cardiology

Volumn 88, Issue 7, 2001, Pages 28-35

  McVeigh, Gary E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; PERINDOPRIL;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ARTERY COMPLIANCE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY BLOOD VESSEL; DRUG EFFECT; DRUG MECHANISM; HEART AFTERLOAD; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LONG TERM CARE; MORBIDITY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESISTANCE BLOOD VESSEL; REVIEW;

EID: 0035478607     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01919-1     Document Type: Article

References (38)

1. National High Blood Pressure Education Program Working Group report on hypertension in the elderly
2. Swedish Trial in Old Patients with Hypertension (STOP-hypertension) analyses performed up to 1992
3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
4. Cardiovascular hypertrophy: Role of angiotensin II and bradykinin
5. Vascular hypertrophy in hypertension: Role of the renin-angiotensin system
6. The blood vessel as a target organ in hypertension: Protective effect of perindopril
7. The renin-angiotensin-aldosterone system: A specific target for hypertension management
8. Angiotensin receptors and their antagonists
9. Effects of peptide vasoconstrictors on vessel structure
10. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
11. Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension
12. The multiple actions of angiotensin II in atherosclerosis
13. The importance of left ventricular hypertrophy in human hypertension
14. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders
15. Vascular effects of ACE inhibition by perindopril
16. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease
17. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril
18. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease
19. Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome
20. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension
21. Pulse pressure, arterial compliance and cardiovascular morbidity and mortality
22. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension
23. Wave travel and reflection in the arterial system
24. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients
25. Vascular effects of perindopril: From experimental to clinical investigation
26. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
27. Arterial compliance by cuff sphygmomanometer: Application to hypertension and early changes in subjects at genetic risk
28. Arterial compliance in essential hypertension
29. Reversion of arterial abnormalities by long-term antihypertensive therapy in large population: The COMPLIOR study
30. Vascular wall thickness in hypertension: The perindopril regression of vascular thickening European Community Trial: PROTECT
31. Angiotensin-converting enzyme inhibition, cell growth, and left ventricular hypertrophy in hypertension
32. Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment
33. Évolution de la masse ventriculaire gauche dans une population de 893 hypertendus: Effets d'une intervention thérapeutique par le perindopril
34. Treatment of hypertension with perindopril reduces plasma atrial natriuretic peptide levels, left ventricular mass, and improves echocardiographic parameters of diastolic function
35. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine
36. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: Perindopril versus isradipine
37. Risk mechanisms in hypertensive heart disease
38. Hypertension: Where have we gone wrong and how can we fix it?